Qbiotics
Brisbane, Australia· Est.
Australian biotech leveraging rainforest‑derived small molecules for oncology and wound‑healing therapies.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Australian biotech leveraging rainforest‑derived small molecules for oncology and wound‑healing therapies.
OncologyWound Healing
Technology Platform
Ecologic™ phenotypic screening platform that leverages rainforest‑derived molecular scaffolds and veterinary disease models to discover novel cell‑signalling small molecules.
Opportunities
Successful Phase II data could unlock licensing deals with major pharma, while the Ecologic™ platform offers a pipeline of novel scaffolds for multiple therapeutic areas.
Risk Factors
Clinical trial failure, high capital requirements for late‑stage development, and reliance on a limited product pipeline.
Competitive Landscape
QBiotics competes with other phenotypic‑screening biotech firms and small‑molecule oncolytics, differentiating itself through rainforest‑derived scaffolds and a veterinary‑to‑human translational model.